Amin, Alpesh

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial

Lobo, S. M., Plantefève, G., Nair, G., Joaquim Cavalcante, A., Franzin de Moraes, N., Nunes, E., Barnum, O., Berdun Stadnik, C. M., Lima, M. P., Lins, M., et al. (2024) · eClinicalMedicine

COVID-19 Clinical Research StudiesRenin-Angiotensin System Studies

Cited by 27

Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients

Amin, A., Jing, Y., Trocio, J., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Medical Economics

Venous Thromboembolism Diagnosis and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 22

Real-world medical cost avoidance when new oral anticoagulants are used versus warfarin for venous thromboembolism in the United States

Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016) · Clinical and Applied Thrombosis/Hemostasis

Venous Thromboembolism Diagnosis and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 20